Time: 3:00pm ET | 12:00pm PT
Duration: 1 Hour
Jennifer Keating Litton, MD is Vice President ad interim of Clinical Research and Professor in the Department of Breast Medical Oncology and Clinical Cancer Genetics at The University of Texas MD Anderson Cancer Center. She holds an additional faculty position in the Graduate School of Biomedical Sciences at The University of Texas Health Sciences Center in Houston. She serves as a member of the National Cancer Center Network National Guidelines Panel for Hereditary Breast and Ovarian Cancer Syndromes and has been appointed to the Breast Immuno-Oncology Task Force of the National Cancer Institute Breast Cancer Steering Committee and Co-Chair of the Society for Immunotherapy of Cancer (SITC) Breast Cancer Subcommittee.
Vanessa M. Lucey, Ph.D., MBA, is the director of the CRI Venture Fund and Anna-Maria Kellen Clinical Accelerator—a global collaboration of more than 90 of the field’s top clinical researchers and over 20 top biopharma companies designed to identify novel combinations of cancer immunotherapies that may hold transformational promise for patients. Vanessa leads and manages the program’s scientific and investment strategy for a $110+ million evergreen venture fund. She also oversees and coordinates activities between CRI's clinical trials management delivery partners as well as various academic and biopharma stakeholders. Additionally, Vanessa manages the CRI Immuno-Oncology Landscape, a drug and clinical trial database to track the evolving field of immunotherapy.
Andrew Berens, M.D., is a Senior Research Analyst at SVB Leerink covering Targeted Oncology. Prior to joining the firm in 2018, Dr. Berens was an Executive Director and Senior Biotechnology Research Analyst at Morgan Stanley focusing on mid and small cap biotechnology companies. Dr. Berens practiced as an emergency medicine physician for a decade before starting his career in equity research. He also worked in the pharma industry at Ikaria Pharmaceuticals, where he was a Senior Director in business development, leading search and development efforts.
Roy Baynes is Senior Vice President Global Clinical Development and Chief Medical Officer at Merck Research Laboratories in Rahway, New Jersey. He was previously Senior Vice President of Oncology, Inflammation and Respiratory Therapeutics at Gilead Sciences and prior to that was Vice President Global Clinical Development and Therapeutic Area (TA) Head for Hematology / Oncology, at Amgen Inc. In the early years of his tenure at Amgen before becoming TA head of Hematology / Oncology in Clinical Development he was TA head for Hematology / Oncology in Global Medical Affairs.
Chris Boshoff is Chief Development Officer for Pfizer Oncology. In this capacity, he is responsible for overseeing clinical research and development activities for Pfizer’s portfolio of 22 cancer medicines and biosimilars across more than 30 indications. He is a member of the Pfizer Global Product Development and Oncology Leadership Teams and Pfizer’s Senior Leadership Council. Chris is part of the PfizerOncology Triad, where he works closely with the Global President and General Manager of Pfizer Oncology and theSenior Vice President & Group Head of Oncology R&D to drive Pfizer Oncology’s strategies, including Business Development and Partnerships.
Daina Graybosch, Ph.D., is a Senior Research Analyst at SVB Leerink covering Immuno-Oncology. Prior to joining the firm in 2018, Dr. Graybosch worked at McKinsey & Company as a Senior Expert and Head of Mckinsey’s Center for Asset Optimization, as well as the U.S. Head of the McKinsey Cancer Center. In these roles, Dr. Graybosch developed several McKinsey solutions that bring data and advanced analytics to pharmaceutical development decisions. In her 11 years at McKinsey, Dr. Graybosch developed a rich understanding of oncology through her work with companies across the value chain, including Pharmaceutical, Diagnostic, Academic Medical Center, and Genomic/Data.